Pancreatic Cancer Research

ResearcherMayo ClinicActive in the last 2 years

Min Deng

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0003-1987-9775; OpenAlex author ID A5028424745, A5122258967. Sources: OpenAlex.

Their work

Papers
4 (first author 0, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
13
Papers, trials and grants by year

2016: 1 paper · 2017: none · 2018: none · 2019: none · 2020: none · 2021: none · 2022: 1 paper · 2023: none · 2024: none · 2025: none · 2026: 2 papers

Papers 4

  1. Combination of PARP and KRAS G12D inhibitors enhances therapeutic efficacy by exploiting vulnerabilities in PDAC. Last author DOI 10.1038/s41467-026-69695-4↗
  2. Author Correction: Combination of PARP and KRASG12D inhibitors enhances therapeutic efficacy by exploiting vulnerabilities in PDAC Last author DOI 10.1038/s41467-026-72371-2↗
  3. METTL16 antagonizes MRE11-mediated DNA end resection and confers synthetic lethality to PARP inhibition in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s43018-022-00429-3↗
  4. HEATR1 Negatively Regulates Akt to Help Sensitize Pancreatic Cancer Cells to Chemotherapy. Co-author DOI 10.1158/0008-5472.can-15-0671↗

Closest collaborators

The 13 strongest of 13 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Zhenkun Lou · 4 shared papers, 2016–2026 · strength 0.73
  2. Xin Xu · 2 shared papers, 2026 · strength 0.58
  3. Changying Li · 2 shared papers, 2026 · strength 0.58
  4. Yu Shi · 1 shared paper, 2022 · strength 0.10
  5. Kaixiong Tao · 1 shared paper, 2022 · strength 0.10
  6. Zhijie Xu · 1 shared paper, 2022 · strength 0.10
  7. Xiangyu Zeng · 1 shared paper, 2022 · strength 0.10
  8. Xinyi Tu · 1 shared paper, 2022 · strength 0.10
  9. Liewei Wang · 1 shared paper, 2016 · strength 0.05
  10. Wenhui Lou · 1 shared paper, 2016 · strength 0.05
  11. Yuan Fang · 1 shared paper, 2016 · strength 0.05
  12. Tongzheng Liu · 1 shared paper, 2016 · strength 0.05
  13. Fang Xie · 1 shared paper, 2016 · strength 0.05

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.